Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Marinus Pharmaceuticals, Inc (MRNS)

Pharmaceutical Preparations

https://www.marinuspharma.com

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

5 RADNOR CORPORATE CENTER SUITE 500, 100 MATSONFORD RD
RADNOR, PA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/31/2014

Market Cap

69,956,680

Shares Outstanding

54,570,000

Weighted SO

54,573,581

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

AKRO --.--%

TERN --.--%

MDGL --.--%

INZY --.--%

VKTX --.--%

ETNB --.--%

CABA --.--%

MIRM --.--%

AMLX --.--%

Beta

1.1250

Last Div

0.0000

Range

1.05-11.26

Chg

0.0500

Avg Vol

903532

Mkt Cap

69956680

Exch

NASDAQ

Country

US

Phone

484 801 4670

DCF Diff

13.7785

DCF

-4.5785

Div Yield

0.0000

P/S

2.3116

EV Multiple

-0.7619

P/FV

-1.5307

Div Yield %

0.0000

P/E

-0.4856

PEG

-0.0104

Payout

0.0000

Current Ratio

2.2829

Quick Ratio

2.1471

Cash Ratio

1.8032

DSO

41.4293

DIO

550.8346

Op Cycle

592.2639

DPO

705.0186

CCC

-112.7547

Gross Margin

0.8933

Op Margin

-4.4011

Pretax Margin

-4.9314

Net Margin

-4.9314

Eff Tax Rate

-0.0223

ROA

-1.7137

ROE

-79.3503

ROCE

-2.6006

NI/EBT

1.0000

EBT/EBIT

1.1205

EBIT/Rev

-4.4011

Debt Ratio

1.0988

D/E

-2.0210

LT Debt/Cap

2.4277

Total Debt/Cap

1.9795

Int Coverage

619.4884

CF/Debt

-1.2590

Equity Multi

-1.8393

Rec Turnover

8.8102

Pay Turnover

0.5177

Inv Turnover

0.6626

FA Turnover

6.8468

Asset Turnover

0.3475

OCF/Share

-2.1111

FCF/Share

-2.1138

Cash/Share

1.1334

OCF/Sales

-3.9807

FCF/OCF

1.0013

CF Coverage

-1.2590

ST Coverage

-7.9375

CapEx Coverage

-767.3057

Div&CapEx Cov

-767.3057

P/BV

-1.5307

P/B

-1.5307

P/S

2.3116

P/E

-0.4856

P/FCF

-0.5800

P/OCF

-0.6016

P/CF

-0.6016

PEG

-0.0104

P/S

2.3116

EV Multiple

-0.7619

P/FV

-1.5307

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 02, 22:30 $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – VINC, VCSA, MRNS, MHLD GlobeNewswire Inc. Jan 01, 00:35 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of Shareholders GlobeNewswire Inc. Aug 03, 14:58 SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS GlobeNewswire Inc. Jul 29, 23:00 MRNS DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS GlobeNewswire Inc. Jul 28, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm

Revenue Product Segmentation